Archive: October 2025
Feature Article
Cancer and Cardiovascular Health: A Multidisciplinary Approach
Abstract: Early detection and improved cancer therapies have led to increases in cancer survivorship. There were 18.1 million cancer survivors in the United States alone in […]
Feature Article
Targeted Immunotherapy in the Treatment of Childhood and Adolescent Mature B-Cell Lymphoma
Abstract: Mature B-cell non-Hodgkin lymphomas (B-NHLs) comprise approximately 40% to 60% of all NHLs among children, adolescents, and young adults. Although overall survival with mature B-NHL […]
Prostate Cancer In Focus
Targeting Prostate-Specific Membrane Antigen in Prostate Cancer
H&O Could you describe the ENZA-p trial that you and your colleagues conducted? LE ENZA-p was a randomized phase 2 trial that took place at 15 […]
Melanoma in Focus
Neoadjuvant Therapy in Melanoma: A New Standard of Care
H&O How do you define neoadjuvant therapy in melanoma? NK In true neoadjuvant therapy, a defined dose and schedule of preoperative therapy are given with the […]
Advances in LLM
Using Imetelstat for Lower-Risk Myelodysplastic Syndromes
H&O Who is eligible for treatment with imetelstat? VS Imetelstat (Rytelo, Geron) is approved for use in adults with myelodysplastic syndromes (MDS) of low to intermediate-1 […]
Letter From the Editor
Letter From the Editor: Patients’ Stories
I love a good book. It’s not often these days that I get to enjoy a novel, cover to cover, over a week or two. Sure, I […]
Gynecologic Cancer in Focus
The Use of Antibody-Drug Conjugates in Gynecologic Cancers
H&O What makes antibody-drug conjugates (ADCs) particularly promising for treating gynecologic cancers in comparison with traditional chemotherapy? JL ADCs are a form of targeted chemotherapy. When […]